Derivation and characterization of an HIV-1 mutant that rescues IP₆ binding deficiency

Daniel Poston¹,², Trinity Zang¹,³ and Paul Bieniasz¹,³*

Abstract

Background: A critical step in the HIV-1 replication cycle is the assembly of Gag proteins to form virions at the plasma membrane. Virion assembly and maturation are facilitated by the cellular polyanion inositol hexaphosphate (IP₆), which is proposed to stabilize both the immature Gag lattice and the mature capsid lattice by binding to rings of primary amines at the center of Gag or capsid protein (CA) hexamers. The amino acids comprising these rings are critical for proper virion formation and their substitution results in assembly deficits or impaired infectiousness. To better understand the nature of the deficits that accompany IP₆ binding deficiency, we passaged HIV-1 mutants that had substitutions in IP₆ coordinating residues to select for compensatory mutations.

Results: We found a mutation, a threonine to isoleucine substitution at position 371 (T371I) in Gag, that restored replication competence to an IP₆-binding-deficient HIV-1 mutant. Notably, unlike wild-type HIV-1, the assembly and infectiousness of resulting virus was not impaired when IP₆ biosynthetic enzymes were genetically ablated. Surprisingly, we also found that the maturation inhibitor Bevirimat (BVM) could restore the assembly and replication of an IP₆-binding deficient mutant. Moreover, using BVM-dependent mutants we were able to image BVM-induced assembly of individual HIV-1 particles assembly in living cells.

Conclusions: Overall these results suggest that IP₆-Gag and Gag-Gag contacts are finely tuned to generate a Gag lattice of optimal stability, and that under certain conditions BVM can rescue IP₆ deficiency. Additionally, our work identifies an inducible virion assembly system that can be utilized to visualize HIV-1 assembly events using live cell microscopy.

Keywords: HIV-1, IP₆, Inositol phosphate, HIV-1 assembly, Imaging

Background

The HIV-1 Gag polyprotein which is composed of the matrix (MA), capsid (CA), spacer peptide 1 (SP1), nucleocapsid (NC), spacer Peptide 2 (SP2), and p6 domains, has central structural and functional roles in the HIV-1 replication cycle. During virion assembly, multimerization of the Gag polyprotein at the plasma membrane, primarily driven by the CA and NC domains, generates immature HIV-1 virions composed of radially oriented Gag hexamers [1–5]. Following assembly, and concomitant with or shortly after nascent particles are released, proteolytic processing of Gag by HIV-1 protease separates the aforementioned Gag domains [6]. The liberated CA protein undergoes a major structural rearrangement to form the mature conical core, composed of a lattice of CA hexamers with 12 CA pentamers, and is the salient feature of particle maturation [7]. Only after maturation are HIV-1 particles able to initiate new cycles of infection.

It has been previously shown that inositol phosphates play a critical role in both HIV-1 assembly and maturation. While assembly of HIV-1 Gag protein in vitro yields immature particles that differ in size and character...
from authentic virions, addition of inositol phosphates to in vitro assembly reactions enables the production of particles that resemble authentic virions [8]. Further work identified inositol hexakisphosphate, or IP6, as the key mediator of this process. IP6 is a ubiquitous cellular polyon containing 5 equatorial phosphates and a single axial phosphate, and facilitates formation of immature HIV-1 Gag lattice by binding to and stabilizing positively-charged rings of primary amines. These rings are formed by lysine residues at Gag positions 290 and 359 (K290 & K359) that are positioned at the center of the immature Gag hexamer [9]. Following the subsequent structural rearrangement of CA that accompanies maturation, IP6 next binds to a second, distinct positively charged ring in the mature CA hexamer formed by arginine residues at CA position 18 (R18, Gag position R150). The R18 ring stabilizes the mature CA hexamer, and is required for viral DNA synthesis in newly infected cells [10–12]. It is thought that IP6 is recruited into virions by interacting with K290 and K359 during immature particle production; this model is consistent with data demonstrating that HIV-1K290A and HIV-1K359A are significantly impaired in both viral production and IP6 packaging, while HIV-1K359A is assembly competent but generates poorly infectious particles [13].

The importance of each of the IP6-coordinating residues has been established, as mutagenesis of any such residue to an alanine (HIV-1R18A, HIV-1K290A, or HIV-1K359A) significantly impairs infectivity in either single cycle or spreading infection assays [9, 13–15]. Additionally, yield of infectious virions is also substantially reduced in cells lacking key enzymes in the IP6 biosynthetic pathway (IPPK or IPMK) or in cells overexpressing MINPP1, a phosphatase that dephosphorylates IP6 [9, 13–15]. The IP6-coordinating amino acids are conserved among diverse lentiviruses, suggesting a general requirement for IP6 [16].

While there is considerable evidence that perturbing IP6 binding impairs HIV-1 replication, further investigation into the precise mechanisms underlying replication deficits is warranted. To better understand the role of IP6, we serially passaged virions containing substitutions in IP6-coordinating residues to identify second-site compensatory mutations that might rescue the resulting infectivity deficits. Accordingly, we found a single substitution that rescued the replication deficit observed in two IP6-binding-deficient mutants. Using CRISPR/Cas9 knockout of IPMK, we show that the second-site substitution restored infectious virion yield despite loss of this IP6 biosynthetic pathway. Strikingly, we also found that treatment with a maturation inhibitor Bevirimat (BVM) rescues infectivity of the IP6-binding-deficient mutant HIV-1K359A. Indeed, using approaches in which the assembly of individual HIV-1 particles is imaged in living cells, we show that addition of BVM can induce the assembly of CA-mutant HIV-1 virions.

Results
Identification of a second-site substitution that restores replication competence to IP6-binding deficient HIV-1 mutants

To identify second site changes that would rescue IP6 binding deficient mutants, we passaged HIV-1 mutants encoding substitutions in IP6-coordinating residues (HIV-1R18A, HIV-1K290A, or HIV-1K359A) in the highly-permissive MT4 T-cell line. Initial attempts, in which MT4 cells were infected with mutant viral stocks, were unsuccessful, likely due to the dramatically impaired fitness of these mutants and consequent inability to establish a sufficiently large population of infected cells to generate revertants. To overcome this problem, we instead co-cultured MT4 cells with virus-producing 293T cells that had been transfected with HIV-1R18A, HIV-1K290A, and HIV-1K359A proviral plasmids that encode GFP in place of nef. After removing the 293T cells, infected MT4 cells were co-cultured with uninfected MT4 cells, until most of the MT4 cells became infected (as monitored by visual inspection of GFP+ cells in the culture). Thereafter, cell-free supernatant was serially passed in MT4 cells (Fig. 1A).

For one mutant, HIV-1K359A, observation of GFP positive cells suggested that an apparently compensatory mutation arose after approximately 2 weeks of passaging. PCR amplification and sequencing of Gag encoding sequences from this culture revealed the presence of a single nucleotide substitution in gag that resulted in a threonine to isoleucine substitution at Gag position 371 (Fig. 1B). No revertant mutants could be obtained for HIV-1R18A or HIV-1K290A. This finding may reflect a greater magnitude of impairment of these particular substitutions, making the generation of revertant mutants more difficult.

To determine whether the T371I mutant rescued the infectivity defect present in HIV-1K359A, we generated a proviral clone, HIV-1K359A/T371I, encoding both mutations and measured the infectious virion yield from proviral plasmid-transfected 293T cells. Addition of the T371I substitution to HIV-1K359A restored infectious virion yield to wild-type levels (Fig. 1C). Although this second-site, apparently compensatory change was identified only in the context of HIV-1K359A, we asked whether the T371I substitution could rescue the HIV-1K290A given purported similar roles of K290 and K359 in binding IP6. Indeed, we found that HIV-1K290A/T371I, unlike HIV-1K290A, yielded similar levels of infectious HIV-1 virions to wild-type HIV-1.
To determine whether the effects of the T371I mutant were evident outside the context of transfected 293T cells, we performed spreading replication assays of HIV-1WT, HIV-1T371I, HIV-1K359A, and HIV-1K359A/T371I in MT4 cells (Fig. 1D) and CEM cells (Fig. 1E). As expected, HIV-1K359A replicated poorly in both cell types.
HIV-1T371I replicated poorly in CEM cells but well in MT4 cells, perhaps reflecting the greater permissiveness of MT4 cells. Importantly however, we found similar phenotypes for HIV-1K359A/T371I in spreading replication assays in both MT4 and CEM cells; namely, addition of the T371I substitution to HIV-1K359A restored replication, with the HIV-1K359A/T371I double mutant exhibiting only a modest delay compared to HIV-1WT in both cell types (Fig. 1D, E).

**Infectious HIV-1K359A/T371I particle yield is not affected by reduction of IP₆ synthesis in virus producing cells**

Because the HIV-1K359A is defective for IP₆ binding we next asked whether HIV-1K359A/T371I retained infectiousness when cellular IP₆ levels were reduced. Using CRISPR/Cas9 we generated 293T cells lacking IPMK, an enzyme in the IP₆ synthetic pathway. Previous work has demonstrated IPMK knockout cells have greatly reduced levels of both IP₅ and IP₆ [13]. To account for potential clonal variation in capacity to generate HIV-1 particles, we used 3 separate IPMK targeting sgRNAs or a corresponding empty vector to generate ten independent single cell clones of IPMK knockout and WT control 293T cells (Fig. 2A). The loss of IPMK was confirmed by DNA sequencing of target loci, which revealed the introduction of frameshift mutations and the absence of intact IPMK alleles. In agreement with previous studies, the yield of infectious HIV-1WT virions from IPMK-deficient 293T cells was significantly decreased, by tenfold (p = 0.0091, Fig. 2A). The yield of HIV-1K359A from 293T cells was greatly reduced compared to wildtype HIV-1 as expected, and was not further reduced by IPMK deficiency (Fig. 2B). Yield of HIV-1K371I was also slightly reduced compared to wildtype but not impacted by IPMK deficiency (Fig. 2C, p = 0.1374). Importantly, the yield of HIV-1K359A/T371I was only marginally reduced compared to wildtype HIV-1 and there was no difference in yield of infectious HIV-1K359A/T371I from WT 293T cells versus IPMK deficient 293T cells (Fig. 2D, p = 0.178).

As IP₆ deficiency impacts both HIV-1 particle production as well as infectivity, we assayed particle levels in the same supernatants from Fig. 2A–D using detection of reverse transcriptase with the SYBR-PERT assay. Importantly, we see the same phenotype for particle production as we do with infectivity assays: production of HIV-1WT particles is impaired in IPMK KO cells, but there are no production deficits for HIV-1K359A, HIV-1T371I, or HIV-1K359A/T371I (Fig. 2E–H). However, while there was a tenfold reduction in HIV-1WT infectivity from IPMK-deficient 293T cells, we only observed a five-fold reduction in particle production in the exact same supernatants.

**Infection of target cells with impaired IP₆ synthesis by HIV-1WT or HIV-1K359A/T371I**

It has been proposed that residues K290 and K359 recruit IP₆ into HIV-1 virions during assembly, thereby providing the source of the IP₆ that binds to and stabilizes the R18 ring in the mature capsid core. The rationale for this idea stems from previous studies which have demonstrated that reduction of cellular IP₆ levels in target cells does not impact susceptibility to incoming infection [13, 14]. Because HIV-1K359A/T371I is fully infectious despite encoding a mutation that is predicted to diminish IP₆ packaging into virions, we next asked whether HIV-1K359A/T371I requires IP₆ in target cells to be maximally infectious. We generated twelve IPMK-deficient MT4 target cell clones and six control clones and performed single cycle infection assays using HIV-1WT and HIV-1K359A/T371I (Fig. 2D, E). In agreement with previous studies [13], there was no difference in the infectiousness of HIV-1WT in WT or IPMK-deficient MT4 target cells (Fig. 2E, p = 0.4331), suggesting that HIV-1K359A/T371I either does not require IP₆ for replication, or that the T371I mutation rescues both replication and IP₆ incorporation.

**Bevirimat rescues infectious virion formation by the IP₆-binding deficient mutant HIV-1K359A**

Notably, the T371I mutation identified herein had been described previously in a different context. Specifically, this substitution was reported to stabilize the immature CA-SP1 lattice, mimicking the effect of maturation inhibitors (MI) [17, 18]. Therefore, we next asked whether maturation inhibitors themselves could rescue the deficit in infectious virion yield exhibited by HIV-1K359A. As a control, we included the previously described assembly-defective, maturation inhibitor-dependent CA mutant HIV-1P289S [18]. We found that that BVM indeed rescued the infectivity of HIV-1K359A and HIV-1P289S in both single-cycle and spreading replication. Specifically, in single cycle assays, BVM increased the yield of infectious HIV-1K359A virions, up to 50-fold, and in a dose-dependent manner (Fig. 3A) from transfected 293T cells. In spreading replication assays, BVM restored HIV-1K359A replication to levels similar to that of BVM-treated wildtype virus in MT4 cells (Fig. 3B). BVM also rescued the spreading replication of HIV-1K359A in CEM cells, indeed in this context the effect of BVM on HIV-1K359A spreading was greater than that on the previously described MI-dependent mutant HIV-1P289S (Fig. 3C).
Fig. 2 HIV-1K359A/T371I is not impaired by lack of cellular IP6. A–D Control or IPMK KO single 293T cell clones were transfected with HIV-1WT (A), HIV-1K359A (B), HIV-1T371I (C), or HIV-1K359A/T371I (D) proviral plasmids. After 48 h, supernatants were collected and titrated on MT4 cells. Each data point represent a different 293T cell clone. Statistical analysis: unpaired Student’s t-test. Alternatively, levels of Reverse Transcriptase in supernatants were quantified using the SYBR-PERT assay (E–H). I, J HIV-1WT (I) or HIV-1K359A/T371I (J) virions were titrated on WT MT4 or IPMK KO MT4 cells and infection quantified by flow cytometry. Each data point represent a different MT4 cell clone. Statistical analysis: unpaired Student’s t-test.

Fig. 3 Bevirimat rescues infectivity of HIV-1K359A. A 293T cells were transfected with HIV-1WT, HIV-1K359A, or HIV-1P289S proviral plasmids in the presence of 0, 1, 5, or 10 μM Bevirimat. After 48 h, supernatants were collected and titrated on MT4 cells and infection quantified by flow cytometry. B, C MT4 cells (B) or CEM cells (C) were infected with HIV-1WT, HIV-1K359A, or HIV-1P289S at an MOI of 0.001. At 16 h post infection, inoculum was washed away and supernatants were collected at the indicated timepoints. Reverse transcriptase activity was measured in the supernatant samples using SYBR-PERT.

(See figure on next page.)
Fig. 3 (See legend on previous page.)
BVM increases release of HIV-1<sub>K359A</sub> virions independently of the viral protease

The interaction between K359 amines and IP<sub>6</sub> likely stabilizes the immature Gag lattice. Similarly, maturation inhibitors are known to bind to the immature Gag hexamers at approximal site and stabilize the immature CA-SP1 lattice [19, 20]. Therefore, we hypothesized that BVM rescue particle formation by HIV-1<sub>K359A</sub> by stabilizing an otherwise destabilized lattice, effectively serving as a functional replacement for IP<sub>6</sub>. To test this idea, we measured the release of HIV-1<sub>K359A</sub> virions from BVM-treated 293T cells by western blotting. BVM indeed increased the yield of HIV-1<sub>K359A</sub> virions, in a dose-dependent manner (Fig. 4A). To confirm that this effect was not due to BVM-mediated inhibition of Gag proteolysis, we performed similar experiments in virions containing an inactivating mutation in protease. We observed a similar dose-dependent increase in immature particle release, even in the context of protease inactivation (Fig. 4B), suggesting that the effect of BVM on HIV-1<sub>K359A</sub> assembly is due to the direct effect of BVM on the immature lattice, not through inhibition of proteolytic cleavage at the Gag-SP1 junction.

Visualization of BVM-induced HIV-1 assembly observed in real time using live cell fluorescence microscopy

The above data strongly suggested that BVM rescues infectivity and release of HIV-1<sub>K359A</sub> by facilitating particle assembly. To directly observe effects on virion assembly, we performed fluorescence microscopy using a novel imaging construct based on HIV-1<sub>NL4-3</sub>, in which Pol has been replaced by an HIV-1 codon-mimicking mNeonGreen, and in which Env and Vpu bear inactivating mutations. The resulting construct, herein referred to as HIV-1 NG, generates Gag-mNeonGreen in place of Gag-Pol during a single cycle of infection, thus allowing visualization of particle assembly as punctae at the plasma membrane.

We generated HIV-1 vectors particle containing this reporter and derivatives (HIV-1 NG<sub>WT</sub>, HIV-1 NG<sub>K359A</sub>).
and HIV-1 NG(P289S) by supplying Gag-Pol and VSV-G in trans. Then, we infected TZM-bl cells in the absence or presence of 5 μM BVM and performed widefield imaging on fixed cells 48 h post infection. In the absence of BVM, cells infected with HIV-1 NG(K359A) and HIV-1 NG(P289S) exhibited primarily diffuse cytoplasmic fluorescence, and fewer punctae than for HIV-1 NG(WT) infected cells, indicating impaired assembly (Fig. 5A). However, when infections were done in the presence of BVM, there were clearly increased numbers of membrane associated punctae in HIV-1 NG(K359A) and HIV-1 NG(P289S) infected cells (Fig. 5A) suggesting BVM is able to directly facilitate particle assembly by these mutants.

This ability to induce HIV-1 particle assembly via addition of an exogenous small molecule has potential applications in imaging and other studies, as an inducible

![Fig. 5 Visualizations of Bevirimat-induced assembly by fluorescence microscopy. A] Fluorescence microscopy of TZM cells infected with a reporter HIV-1 virus encoding mNeon Green in place of Pol (HIV-1 NG) to visualize assembly. Representative images 48 h-post-infection of HIV-1 NG(WT), HIV-1 NG(K359A) infected in the absence or presence of 5 μM BVM. Quantification of Gag-NG punctae per image depicts mean ± SD for images from (A). B] Representative time lapse images of TZM cells infected with HIV-1 NG(P289S) +/- treatment with 5 μM BVM at 26 h post infection. Image acquisition began immediately after BVM addition. Image labels: Hours:Minutes:Seconds post BVM addition. Quantification of Gag-NG punctae per timepoint depicts mean ± SD for images from (B). C] Representative time-lapse images of TZM cells treated with BVM at 26 h post infection with HIV-1 NG(P289S). Image labels: Hours:Minutes:Seconds post BVM addition. Quantification of Gag-NG punctae per timepoint depicts mean ± SD for images from (C).
particle assembly system. In order to test the possible utility of this approach, we performed live cell widefield imaging studies using HIV-1 NGp289S as this mutant displayed a greater responsiveness to BVM-induced assembly (see Figs. 3A, B, 4B, and 5A). We infected TZM-bl cells in the absence of BVM and then, at 26 h after infection, added BVM 5 μM and began acquiring images at 30 min intervals. In the absence of BVM, few punctae are apparent in HIV-1 NGp289S infected cells, even after 12 h of imaging (Fig. 5B, Additional files 1, 2). However, in the BVM-treated cells, substantially more punctae were evident, as soon as 30 min after BVM addition (Fig. 5B, Additional files 3, 4).

Given that such striking differences could be observed as early as 30 min post BVM addition, we repeated these experiments with increased time resolution. TZM-bl cells were infected with HIV-1 NGp289S for 26 h and treated with BVM as above, followed by immediate image acquisition at 3 min intervals. Assembly of HIV-1p289S was rapidly induced by BVM (Fig. 5C, Additional files 5, 6) with substantial numbers of punctae forming within 30–120 min. We performed similar experiments using TIR-FM imaging and quantified the presence of Gag-NG punctae over time, with similar results. Specifically, in the absence of BVM there were very few punctae evident at the plasma membrane (Fig. 6A, B, Additional files 7, 8). However, shortly after the addition of BVM, numerous punctae rapidly formed at the plasma membrane (Fig. 6, Additional files 9, 10). These data provide proof of principle that such a system could be used to experimentally manipulate HIV-1 assembly for imaging or functional studies.

Discussion

Here, we report the identification of a single amino acid substitution (T371I) that rescues the replication of the defective, IP6-binding deficient mutant HIV-1K359A. Despite several attempts we were unable to generate revertant mutants for HIV-1K290A and HIV-1R18A (although follow-up studies demonstrated that the T371I substitution rescues HIV-1K290A as well as HIV-1K359A). The inability to generate revertant mutants for HIV-1R18A and HIV-1K290A is likely due to more substantial impairment. Indeed, previous groups have shown that HIV-1K290A is impaired to a greater extent than HIV-1K359A, potentially because K290 binds the 5 equatorial phosphates on IP6 while K359 coordinates the single axial phosphate, suggesting a greater role for K290 in coordinating IP6 [13]. The inability to generate a revertant mutant rescuing HIV-1R18A could be explained by functions of this residue in addition to coordinating IP6 such as recruitment the cellular protein FEZ1 or as service as a conduit for dNTPs into the mature core [10, 11, 21, 22].

HIV-1K359A/T371I was fully infectious despite containing a mutation (K359A) that renders VLP assembly unresponsive to IP6 in vitro and which substantially impairs IP6 incorporation into virions [9, 13]. Indeed, we found no significant reduction in yield of HIV-1K359A/T371I from IPMK KO 293T cells, in contrast to WT HIV-1. This finding suggests that HIV-1K359A/T371I is no longer dependent on IP6 or requires substantially lower concentrations of IP6 in virus producing cells.

In addition to its role in promoting immature particle assembly, IP6 has also been implicated in stabilizing the mature lattice and promoting viral DNA synthesis by binding to a positively charged pore formed by R18 residues in the mature CA lattice [10, 21]. Previous studies proposed that the source of the IP6 required to stabilize the mature lattice in virions is selective recruitment by K290 and K359 residues, with IP6 being liberated to bind R18 residues following disruption of the immature lattice after proteolysis [9, 10]. In agreement with previous studies, we found that IPMK KO target MT4 cells were fully susceptible to infection by HIV-1WT, indicating that IP6 from target cells is not required to initiate a productive cycle of infection [13]. However, we also found no difference in the infectiousness of HIV-1K359A/T371I in WT and IPMK KO MT4 target cells. This may reflect the possibility that other polyanions can fulfil a post assembly role. Indeed, recent studies demonstrated that other polyanions in mammalian cells such as glucose-1,6-bisphosphate can stabilize mature HIV-1 cores in vitro [23]. Alternatively, a very recent report has demonstrated that addition of the T371I substitution can rescue IP6 incorporation in HIV-1K359A virions to near WT levels [24]. Nevertheless, our data utilizing genetic ablation of the IP6 synthetic machinery suggests that the T371I substitution confers reduced dependence on cellular inositol phosphate levels for virion assembly. Indeed, while production of HIV-1WT was impaired in IPMK KO cells, there was no impairment of HIV-1T371I or HIV-1K359A/T371I in these cells. Thus HIV-1T371I and HIV-1K359A/T371I retains infectiousness even in the setting of reduced cellular IP6 levels, implying at least some level of IP6 independence, even if IP6 is incorporated into virions in the context of the HIV-1K359A/T371I double mutant. Alternatively, the lack of impairment of HIV-1T371I or HIV-1K359A/T371I in the setting of reduced cellular IP6 levels maybe be due to the T371I substitution itself increasing affinity of the lattice for IP6, thus rendering virions less responsive to a reduction in cellular IP6 levels. This notion is consistent with the recent report by Mallery et al. [24], demonstrating that the T371I substitution rescues incorporation of IP6 in HIV-1K359A.

The T371I substitution, identified herein as a compensatory mutation that rescues infectivity deficit found in
Fig. 6 Visualization of Bevirimat-Induced assembly by TIR-FM. A TIR-FM microscopy of TZM cells infected with HIV-1<sub>P2895</sub> NG. Representative time-lapse images of TZM cells treated with BVM at 28 h post infection. Image labels: Hours:Minutes:Seconds post BVM addition. B Quantification of punctae per time point depicts mean ± SD for images from A.
HIV-1_{K359A} has previously been reported to rescue the infectivity of virions containing substitutions that confer resistance to maturation inhibitors (MIs). These substitutions render HIV-1 assembly-defective in the absence of MIs [18] and the T371I substitution was shown to stabilize the CA-SP1 lattice in this context, effectively mimicking the action of MIs [17]. Because the T371I substitution apparently mimics the effect of MIs, we hypothesized that MIs might also rescue the infectivity of HIV-1_{K359A}. Strikingly, we found that this was the case, and found that BVM can stimulate the assembly and release of HIV-1_{K359A}. That the stabilizing effects of both the T371I substitution and BVM can compensate for the lack of IP₆ coordination in HIV-1_{K359A} provides in vivo mechanistic support for the model proposed by Dick et al.: i.e. that binding of IP₆ to K290 and K359 residues stabilizes the immature lattice to drive particle assembly. Interestingly, while Mallery et al. [24] also demonstrated that MIs rescued HIV-1_{K359A}, they observed that PF-46396, but not BVM, rescued infection. This is potentially due to differences in the concentration of BVM used (5.0 µM vs 0.5 µM).

The ability to promote assembly via addition of a small molecule has potential utility in imaging and other studies of HIV-1 assembly. Indeed, when performing live cell time-lapse imaging, we observed BVM-induced assembly on the timescale of minutes. Such an experimental approach has potential utility for studying the sequence of events in HIV-1 virion assembly, such as RNA packaging, ESCRT protein recruitment, and protease activation, where virion assembly can be rapidly and (potentially) reversibly induced in real time simply by addition of a small molecule.

Together, these data support a model whereby stability of the immature CA lattice is finely tuned, with IP₆ coordinating and stabilizing the otherwise repulsive positive charges of K290 and K359 to drive assembly. Manipulations that cause IP₆ binding deficiency, either mutagenesis of K359 or decreasing IP₆ levels in producer cells, destabilize the immature lattice and decrease production of progeny virions. Conversely, manipulations such as the T371I substitution or treatment of HIV-1_{WT} with BVM, hyper-stabilize the immature lattice in the wild type context and decrease HIV-1 infectivity. However, either the T371I substitution or BVM treatment are able to rescue virion assembly and infectiousness in the context of IP₆ deficiency. Understanding how small molecules such as BVM or IP₆ can enhance Gag lattice stability can provide new tools to study virion assembly and potential avenues for antiretroviral therapeutics.

Conclusion
We identified a single-site revertant mutation, T371I, that rescues replication competence of the IP₆-binding-deficient mutant HIV-1_{K359A}. Using CRISPR/Cas9 to genetically ablate IP₆ biosynthesis, we showed that these resulting HIV-1_{K359A/T371I} virions are less dependent on cellular inositol phosphate levels. Remarkably, we also found that the maturation inhibitor BVM could restore the assembly and replication of HIV-1_{K359A} and developed an inducible particle assembly system using BVM-dependent HIV-1 mutants. In addition to providing insight on Gag-Gag and Gag-IP₆ interactions during HIV-1 assembly, our work also identifies an inducible virion assembly system that can be used in investigating HIV-1 assembly events in living cells.

Materials and methods
Cells and media
293T cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal calf serum and gentamycin. MT4 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco) supplemented with 10% fetal calf serum and gentamycin. Cells were maintained at 37 °C and 5% CO₂. All transfections with viral plasmids were performed with polyethyleneimine.

Plasmid construction
All full-length proviral plasmids used in this study were based on the HIV-1 clone NHG, a previously described HIV-1 clone that encodes GFP in place of Nef (Accession number: JQ585717) [25]. Mutant viruses were derived from this parental plasmid using primer mutagenesis with fragments assembled into NHG digested with SpeI and SbfI using NEB HiFi DNA Assembly Master Mix according to the manufacturer’s instructions. Primers used for mutagenesis include: K359A F: 5ʹ-CCGGCC ATGCTGCAAGATTTTG; K359A R: 5ʹ-CAAATAC TCTTGAGCGCATGGCCGG; T371I F: 5ʹ-GCAATGACG CAACTAAATCCACGCTACC; T371I R: 5ʹ-GGT AGCTGGATTATTACTTGCTCATTGC; P289S F: 5ʹ-CATAAGCAAGGAAGTAAACGCCTTGTAG AG; P289S R: 5ʹ-CTTAAAAGGTTCTTATTACCTTCTCTGTCTATTG; R57G F: 5ʹ-TGCTAGTAGGACAGATGATG ATC; R57G R: 5ʹ-GATCATACTGTCTCATTGGTA. The imaging construct HIV-1 NG was derived from NL4-3. The region of NL4-3 encoding Pol was deleted from bp 2294–4813 and a unique XbaI was added at bp 2301; Vpu was deleted and Env was truncated by removing bp 6056–7250 inserting Nhel at 6056. These deletions and restriction sites were created through overlap PCR and cloned into NL4-3 via Spel and Nhel (NL4-3 BssHII 5ʹ-GCTGAAGCGCGCACGCGCAAGAGCCG 5ʹ-CTG
AAGCGCGACAGGAAAAAGGCGAGG and dPol Xba AS 5'-CTACTATTTGCTCCCCTGACACTCTAGCTA CTACTTTATGTGACGAGGGTTGCG; dPol Xba S 5'-CGGACCCCTCGACATATAGTAGTC TAGATGCGAGGGAGAAGAAAATAG and dPvu dENV Nhe1 AS 5'-CTCTCCTCGTACCAATATGACT GCTTTGTATA. The sequence encoding neon green (NG) was codon optimized to have nucleotide composition and codon usage similar to that of Pol using the Codon Optimization On-Line Tool from Singapore University (http://cool.syncti.org) and was synthesized by GeneArt. Neon Green was fused into the p6* frame of Pol through overlap PCR and inserted via SphI and XbaI (NL4-3 SphI 5’ AGTGTGCAAGGAGGCTATGTGACACC , Pol-NG AS 5’-CATGTTATCTCTCTGCGCTTGTGTATGACCCTTTATGTGACGAGGGTTGCG; Pol-NG S 5’-TGCGACGGACCTCTGCACACATAAAAGATGTGCTAGCAAGGAGGAGTAGATG, NG Xba 5’-CTCTCCTCTAGACTACTTTGACAGTCTGTCATGCCC). Mutagenesis of this construct was accomplished using the same primers as above.

Viral stock production
293T cells were seeded at 6 × 106 cells per 10 cm dish and transfected the next day using polyethylenimine. 8 h post transfection, cells were placed in fresh medium. For generation of full-length virus, 293T cells were transfected with 15 µg of proviral plasmid. For generation of imaging constructs, 293T cells were transfected with 6 µg of proviral plasmid, 6 µg of SYN-GP, and 1.2 µg of VSV-G. At 48 h post transfection, supernatants were harvest and passed through a 0.22 µM filter. Titer of full-length infectious viruses was determined by serial dilution on MT4 cells. At 48 h post infection, cells were fixed with 4% PFA and assessed via flow cytometry. Titer of imaging constructs was determined by serial dilution on TZM-bl cells. 48 h post infection, cells were fixed with 0.5% glutaraldehyde and stained with X-gal to visualize number of infected foci.

Generation of IPMK KO cell lines
The IPMK-targeting guides g1: ATGTACGGAGGAGC AAAGT; g2: GTGTTGCACTGATCGCGCTGGT; or g3: CCGGCCACCTGATGGCGAGG were designed using the Broad Institute GPP Web Portal and cloned into lentCRISPRv2 bearing a Hygromycin resistance cassette digested with BsmBI. lentCRISPRv2 was a gift from Feng Zhang (Addgene plasmid # 52961; http://n2t.net/addgene:52961; RRID:Addgene_52961). VLPs were prepared as above, with the exception that 1 × 106 293Ts/well were seeded in a 6 well plate and transfected the next day with 1 µg lentCRISPRv2, 1 µg of Gag-Pol, and 0.2 µg of VSV-G. At 48 h post transduction of target cells with lentCRISPRv2, cells were placed in selection with 100 µg/mL Hygromycin for ~10–14 days. Single cell clones were obtained by limiting dilution, and editing was verified by amplifying and sequencing target loci using primers: IPMK Seq F: 5’-CGCTTCTGGCTTCGGTATTG and IPMK Seq R: 5’-GGATTTGGGCTGACACCATG and assessment using Synthego ICE, which identifies Indel frequency in Sanger sequencing data (Synthego Performance Analysis, ICE Analysis. 2019. v2.0.). Control cells were obtained similarly, using a lentCRISPRv2 plasmid not harboring a sgRNA cassette.

Single cycle infectivity assays
WT control or IPMK KO 293T cells were seeded at 2.5 × 105 cells/well in a 24 well plate and transduced with 625 ng of HIV-1WT, HIV-1K359A, or HIV-1K359A/T371I proviral plasmids. Virions were prepared as above and tittered on MT4 cells. 24 h post infection, Dextran Sulfate was added (50 µg/mL) to limit infection to a single round. 48 h post infection, cells were fixed with 4% PFA and assessed via flow cytometry.

Spreading assays
5 × 104 cells per well were seeded in a 96 well plate and infected at an MOI of 0.001. 16 h post infection, cells were washed three times and placed in 5 µM BVM or DMSO control. Supernatants were collected at indicated timepoints, and levels of reverse transcriptase were quantified using the SYBR-PERT assay as previously described [26].

Western blotting
293Ts were seeded 5 × 105 cells/well in a 12 well dish and transfected the next day with 1.25 µg proviral plasmid. 48 h post transfection, cell lysates and virions pelleted through 20% sucrose (14,000xg for 90 min at 4 °C) were separated on a NuPage 4–12% Bis–Tris Gel (Invitrogen) and subsequently blotted onto a nitrocellulose membrane. Blots were blocked with Intercept Blocking Buffer (Li-Cor) and probed with primary antibody along with a corresponding IRDye 800CW- or IRDye 680-conjugated secondary antibody. Images were acquired using an Odyssey scanner (Li-Cor Biosciences). HIV-1 CA was detected using a human monoclonal anti-p24 (NIH AIDS Reagent Catalog #530).

Imaging
5 × 104 TZM-bl cells per well were plated in a LabTek Chamber Slide and infected the following day with
indicated imaging construct at an MOI of 1. For fixed samples, cells infected in the presence or absence of 5 µM BVM were fixed 48 h post infection and imaged on a DeltaVision OMX SR imaging system using a 60X Widefield oil immersion objective (Olympus) with an exposure time of 50 ms, 10% Transmission, A488 nm laser. For live-cell samples, image acquisition began 26 h post infection, with cells placed in the presence or absence of 5 µM BVM at the time of image acquisition. Images were acquired at 37 °C, 5% CO2 at indicated timepoints using a 60X Widefield oil immersion objective with an exposure time of 45 ms, 5% Transmission A488 nm laser. For TIRFM, cells were imaged approximately 28–30 h post infection in the presence or absence of 5 µM BVM at 37 °C, 5% CO2. Images were acquired every 1 min for 90 min using a 60X RING-TIR-FM objective (Olympus Apo N 60X 1.49 Oil) with an exposure time of 100 ms, 10% Transmission A488 nm laser. Representative images were acquired, and all images were analyzed using Fiji (https://fiji.sc/). Briefly, images were auto thresholded and Gag-NG punctae quantified using the Analyze Particles function in Fiji. Reported is the mean ± SD for displayed images (n = 2 per condition).

Graphing and statistical analysis
All graphs and corresponding statistical analyses were produced and analyzed with Graphpad Prism.

Abbreviations
BVM: Bevirimat; CA: Capsid protein; IP6: Inositol hexaphosphate; MA: Matrix; MI: Maturation inhibitor; NC: Nucleocapsid; SP1: Spacer peptide 1; SP2: Spacer peptide 2.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12977-021-00571-3.

Additional file 1. HIV-1 NGP289S live cell widefield microscopy. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the presence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 30 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 2. HIV-1 NGP289S live cell widefield microscopy. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the absence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 30 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 3. HIV-1 NGP289S live cell widefield microscopy. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the presence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 30 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 4. HIV-1 NGP289S live cell widefield microscopy. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the presence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 30 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 5. HIV-1 NGP289S live cell widefield microscopy at increased time resolution. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the presence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 3 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 6. HIV-1 NGP289S live cell widefield microscopy at increased time resolution. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the presence of 5 µM BVM. Image acquisition began immediately after BVM addition. Images were acquired every 3 min. Movie labels: Hours:Minutes:Seconds post BVM addition.

Additional file 7. HIV-1 NGP289S RING-TIR-FM. TZM cells infected with HIV-1 NGP289S and imaged 26 h post infection in the absence of 5 µM BVM using RING-TIR-FM fluorescence microscopy. Image acquisition began immediately after BVM addition and images were acquired every 60 s. Image labels: Hours:Minutes:Seconds post BVM addition.

Additional file 8. HIV-1 NGP289S RING-TIR-FM. TZM cells infected with HIV-1 NGP289S and imaged 28 h post infection in the absence of 5 µM BVM using RING-TIR-FM fluorescence microscopy. Image acquisition began immediately after BVM addition and images were acquired every 60 s. Image labels: Hours:Minutes:Seconds post BVM addition.

Additional file 9. HIV-1 NGP289S RING-TIR-FM. TZM cells infected with HIV-1 NGP289S and imaged 28 h post infection in the presence of 5 µM BVM using RING-TIR-FM fluorescence microscopy. Image acquisition began immediately after BVM addition and images were acquired every 60 s. Image labels: Hours:Minutes:Seconds post BVM addition.

Additional file 10. HIV-1 NGP289S RING-TIR-FM. TZM cells infected with HIV-1 NGP289S and imaged 28 h post infection in the presence of 5 µM BVM using RING-TIR-FM fluorescence microscopy. Image acquisition began immediately after BVM addition and images were acquired every 60 s. Image labels: Hours:Minutes:Seconds post BVM addition.

Acknowledgements
We thank members of the Bieniasz lab for helpful discussions. The content is solely the responsibilities of the authors and does not necessarily represent the official views of the National Institutes of Health.

Authors’ contributions
DP and PB conceived and designed the experiments. DP and TZ performed the experiments. DP and PB analysed and interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the NIAID; R01AI050111 and R01AI150998 (to PDB). DP was supported by a Medical Scientist Training Program grant from the NIH (T32GM07739) and the Weill Cornell/ Rockefeller/ Sloan Kettering Tri-Institutional MD-PhD Program and by the NIAID (F30AI157898).

Availability of data and materials
The data and reagents used in this study are available from the corresponding author based on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The Authors declare no competing interests.
References

1. Freed EO. HIV-1 assembly, release and maturation. Nat Rev Microbiol. 2015;13(8):484–95.
2. Dorfman T, Bukovsky A, Ohagen A, Hoglund S, Gottlinger HG. Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol. 1994;68(12):8180–7.
3. Borsetti A, Ohagen A, Gottlinger HG. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J Virol. 1998;72(11):9313–7.
4. Nermut MV, Hockley DJ, Jowett JB, Jones IM, Garreau M, Thomas D. Fullerenelike organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology. 1994;198(1):288–96.
5. Jouvenet N, Neil SJD, Bess C, Johnson MC, Virgen CA, Simon SM, et al. Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol. 2006;4(12):e435.
6. Coffin JM, Hootnick DJ, Jowett JB, Jones IM, Garreau M, Thomas D. Fullerenelike organization of HIV gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology. 1994;198(1):288–96.
7. Sundquist WI, Kräusslich H-G. HIV-1 assembly, budding, and maturation. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1997.
8. Campbell S, Fisher RJ, Towler EM, Fox S, Issaq HJ, Wolfe T, et al. Modulation of HIV-1 capsid stabilization by inositol hexakisphosphate (IP6). Sci Adv. 2015;13(8):484–95.
9. Dick RA, Zadrozny KK, Xu C, Schur FKM, Lyddon TD, Ricana CL, et al. Inositol phosphates are assembly co-factors for HIV-1. Nature. 2018;560(7719):509–12.
10. Mallery DL, Marquez CL, McEwan WA, Dickson CF, Jacques DA, Anandapadamaranab M, et al. IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis. Elife. 2018;7:e35335.
11. Xu C, Fischer DK, Rankovic S, Li W, Dick R, Runge B, et al. Permeability of the HIV-1 capsid to metabolites modulates viral DNA synthesis. BioRxiv. 2020.
12. Yu A, Lee EMY, Jin J, Voith GA. Atomic-scale characterization of mature HIV-1 capsid stabilization by inositol hexakisphosphate (IP6). Sci Adv. 2020;6(538):eaba6465.
13. Mallery DL, Faysal KMR, Kleinpeter A, Wilson MSC, Vaysburd M, Fletcher AJ, et al. Cellular IP6 levels limit HIV production while viruses that cannot efficiently package IP6 are attenuated for infection and replication. Cell Rep. 2019;29(12):3983–3996.e4.
14. Ricana CL, Lyddon TD, Dick RA, Johnson MC. Primate lentiviruses require Inositol hexakisphosphate (IP6) or inositol pentakisphosphate (IP5) for the production of viral particles. PLoS Pathog. 2020;16(8):e1008646.
15. Sova GA, Aiken C. Inositol phosphates promote HIV-1 assembly and maturation to facilitate viral spread in human CD4+ T cells. PLoS Pathog. 2021;17(11):e1009190.
16. Dick RA, Xu C, Morado DR, Krawchuk V, Ricana CL, Lyddon TD, et al. Structures of immature EIAV Gag lattices reveal a conserved role for IP6 in lentivirus assembly. PLoS Pathog. 2020;16(11):e1008277.
17. Fontana J, Keller PW, Urano E, Ablan SD, Steven AC, Freed EO. Identification of an HIV-1 mutation in spacer peptide 1 that stabilizes the immature CA-SP1 lattice. J Virol. 2016;90(2):972–8.
18. Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO. Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. PLoS Pathog. 2012;8(11):e1002997.
19. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol. 2011;85(4):1420–8.
20. Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, et al. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology. 2011;8:101.
21. Jacques DA, McEwan WA, Hilditch L, Price AJ, Towers GJ, James LC. HIV-1 uses dynamic capsid pores to import nucleotides and fuel encapsidated DNA synthesis. Nature. 2016;536(7616):349–53.
22. Huang P-T, Summers BJ, Xu C, Perilla JR, Malikov V, Naghavi MH, et al. FEZ1 is recruited to a conserved cofactor site on capsid to promote HIV-1 trafficking. Cell Rep. 2019;28(9):2373-2385.e7.
23. Dostálková A, Kaufman F, Kličová I, Vokátá B, Ruml T, Rumlůvá M. In vitro quantification of the effects of IP6 and other small polyanions on immature HIV-1 particle assembly and core stability. J Virol. 2020;94:e00991-20.
24. Mallery DL, Kleinpeter AB, Renner N, Faysal KMR, Novikova M, Kiss L, et al. A stable immature lattice packages IP6 for HIV capsid maturation. Sci Adv. 2021;7(11):eabe4716.
25. Wilson SJ, Schoggins JW, Zang T, Kutiya SB, Jouvenet N, Alim MA, et al. Inhibition of HIV-1 particle assembly by 2',3'-cyclic-nucleotide 3'-phosphodiesterase. Cell Host Microbe. 2012;12(4):585–97.
26. Pizzato M, Erwine Q, Bonsall D, Kaye S, Maurit D, McClure MD. A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods. 2009;156(1–2):1–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.